findmyKOL

Christopher Flowers, MD

Enriched profile

Division Head, Division of Cancer Medicine; Professor and Chair, Department of Lymphoma/Myeloma · The University of Texas MD Anderson Cancer Center

ORCIDNPI
Region🇺🇸 Houston, TX · South Central · United StatesSpecialtyHematology / OncologyFocusLymphoma Diagnosis and Treatment+4
Active KOLLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2019–2025

Christopher Flowers is Division Head, Division of Cancer Medicine; Professor and Chair, Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 1,171 publications with 37,875 citations (h-index 83); ClinicalTrials.gov lists 4 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Christopher Flowers, M.D., is Division Head, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, Houston, TX. The public record shows 1,171 publications with 37,875 citations (h-index 83), centered on Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, CAR-T cell therapy research. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 19 companies, 2 NIH-funded awards (2019–2025).

  • Most recent indexed publication: 2026 · Blood cancer journal
  • Top research focus: Lymphoma Diagnosis and Treatment
  • 4 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 19 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Lymphoma3 trialsLymphoma, Follicular1 trialLymphoma, B-Cell1 trialAnterior Cruciate Ligament Injuries1 trialLymphoma, Non-Hodgkin1 trialHodgkin Disease1 trialLeukemia (AML/ALL/CML/CLL)

Research focus

OpenAlex concept fingerprint
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchCAR-T cell therapy researchViral-associated cancers and disordersCNS Lymphoma Diagnosis and Treatment

Drugs & molecules

across trials, industry payments and publications
Polivygeneric · Polatuzumab vedotinClinical trialsIndustry payments16Publications1RituximabClinical trials1Industry paymentsPublications6Brukinsageneric · ZanubrutinibClinical trialsIndustry payments4Publications1

Works with

trial sponsors and companies reporting payments
Genentech, Inc.Clinical trialsIndustry payments18Chugai Pharmaceutical Co., Ltd.Clinical trialsIndustry payments7MorphoSys AGClinical trialsIndustry payments6

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,171publications

Distinct works indexed by OpenAlex, matched via ORCID; 53 in PubMed.

37,875citations

Total citations across indexed works.

83h-index

Hirsch index (OpenAlex). i10-index 378.

Clinical & industry

trials, payments and federal funding
4clinical trials

Investigator role on registered studies.

View trials
19companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
2NIH grants · 2019–2025

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

19 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2022)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Anti-infectives

    100%
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor100%
    Valacyclovir100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

2 NIH research awards on record, funded 20192025 per NIH RePORTER. The latest:

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Loretta J. Nastoupil260Jason R. Westin154Jonathon B. Cohen149

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/christopher-flowers-md-c03bd60f

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • LinkedIn

    linkedin.com/in/christopherrflowersmd

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • X / Twitter

    x.com/ChrisRFlowersMD

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com

Mentions by others

where others cite or feature them
  • Other

    cancer.net/blog/podcasts/research-highlights-2021-american-society-hematology-annual-meeting-with-christopher-flowers-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.net
  • X / Twitter

    x.com/CarinHagberg/status/1948773812914299143

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com
  • X / Twitter

    x.com/SocietyofHemOnc/status/1962187919881646487

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com
6 more mentions behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • Board Certified

    Medical Oncology

    2004
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • M.S.

    Pharmaceutical Outcomes Research & Policy Program, University of Washington

    2002
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • Board Certified

    Internal Medicine

    2001
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • M.D.

    Stanford University School of Medicine

    1997
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • M.S.

    Medical Information Sciences, Stanford University

    1997
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • B.A.

    Human Biology/Humanities, Stanford University

    1991
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org

Editorial & leadership roles

journal and society appointments
  • Special Expert

    NCI Lymphoma Steering Committee

    2028
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • Chair-Elect

    Lymphoma Research Foundation Scientific Advisory Board

    2025
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • Associate Editor

    Lymphoma Panel, Cancer.Net

    2021
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
3 more roles behind the reveal.Reveal →

Awards & honors

honors on the public record
2 more awards behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution
  • Former Professor of Hematology & Medical Oncology

    Emory University School of Medicine, and Director, Emory Healthcare-Lymphoma Program, Winship Cancer Institute

    2019
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mdanderson.org

Media & interviews

press, podcasts and appearances
1 more media item behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.